We came across a bullish thesis on Novo Nordisk A/S (NVO) on Disruptive analytics’ Substack by Magnus Ofstad. In this article ...

Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. Read more.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Novo Nordisk (NVO) has released an update. Novo Nordisk has disclosed recent transactions involving the purchase of 1,300 American Depositary Receipts (ADRs) by its board members and executives. This ...

Novo Nordisk reports lower-than-expected Q3 results, missing both earnings and revenue estimates. Management updates 2024 ...

In any case, new support levels are usually revised to the database at the beginning of the next trading session. Short NVO ...

In a report released today, Sachin Jain from Bank of America Securities maintained a Buy rating on Novo Nordisk (NVO – Research Report). The company’s shares opened today at $106.81. According to ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

Welcome to the third-quarter 2024 Novo Nordisk A/S earnings conference call. [Operator instructions] Please be advised that ...

"We have seen an alarming rise in diabetes over the past three decades, which reflects the increase in obesity, compounded by the impacts of the marketing of unhealthy food, a lack of physical ...